NCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
Clinical Trials
14 trialsNCT03631043 2025-12-19
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT05565638 2025-09-25
PROFAST
Dana-Farber Cancer Institute
Phase NA Completed
NCT03951220 2025-08-19
LOOMIS
Oxford University Hospitals NHS Trust
Completed
NCT02916771 2025-08-11
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00112827 2025-06-06
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT03792763 2025-02-11
DEFENCE
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT04615572 2024-10-28
Screening to Improve Survival in AL Amyloidosis
Tufts Medical Center
Completed
NCT02903381 2023-06-13
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02279394 2023-06-09
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02492750 2020-03-25
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT01884688 2017-04-17
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma
University of Arkansas
Phase 2 Completed
NCT01955395 2017-03-16
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
Massachusetts General Hospital
Phase NA Completed
NCT00480363 2013-07-31
QUIREDEX
PETHEMA Foundation
Phase 3 Completed